Hindman Andrew A. 4
4 · Theravance Biopharma, Inc. · Filed May 24, 2022
Insider Transaction Report
Form 4
Hindman Andrew A.
SVP, Chief Financial Officer
Transactions
- Tax Payment
Ordinary Shares
2022-05-20$8.74/sh−3,365$29,410→ 479,183 total
Footnotes (2)
- [F1]Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.
- [F2]Includes 1,263 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 13, 2022.